Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain

Abhishek Sharma, Weiyi Toy, Valeria Sanabria Guillen, Naina Sharma, Jian Min, Kathryn E. Carlson, Christopher G. Mayne, Shengjia Lin, Michael Sabio, Geoffrey Greene, Benita S. Katzenellenbogen, Sarat Chandarlapaty, John A. Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

A major risk for patients having estrogen receptor α (ERα)-positive breast cancer is the recurrence of drug-resistant metastases after initial successful treatment with endocrine therapies. Recent studies have implicated a number of activating mutations in the ligand-binding domain of ERα that stabilize the agonist conformation as a prominent mechanism for this acquired resistance. There are several critical gaps in our knowledge regarding the specific pharmacophore requirements of an antagonist that could effectively inhibit all or most of the different mutant ERs. To address this, we screened various chemotypes for blocking mutant ER-mediated transcriptional signaling and identified RU58668 as a model compound that contains structural elements that support potent ligand-induced inhibition of mutant ERs. We designed and synthesized a focused library of novel antagonists and probed how small and large perturbations in different ligand structural regions influenced inhibitory activity on individual mutant ERs in breast cancer cells. Effective inhibition derives from both nonpolar and moderately polar motifs in a multifunctional side chain of the antagonists, with the nature of the ligand core making important contributions by increasing the potency of ligands possessing similar types of side chains. Some of our new antagonists potently blocked the transcriptional activity of the three most common mutant ERs (L536R, Y537S, D538G) and inhibited mutant ER-mediated cell proliferation. Supported by our molecular modeling, these studies provide new insights into the role of specific components, involving both the ligand core and multifunctional side chain, in suppressing wild-type and mutant ER-mediated transcription and breast cancer cell proliferation.

Original languageEnglish (US)
Pages (from-to)3374-3384
Number of pages11
JournalACS chemical biology
Volume13
Issue number12
DOIs
StatePublished - Dec 21 2018

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Ligands
Cell proliferation
Breast Neoplasms
Cell Proliferation
Molecular modeling
Transcription
Libraries
Conformations
Estrogens
Cells
Neoplasm Metastasis
Recurrence
Mutation
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Sharma, A., Toy, W., Guillen, V. S., Sharma, N., Min, J., Carlson, K. E., ... Katzenellenbogen, J. A. (2018). Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS chemical biology, 13(12), 3374-3384. https://doi.org/10.1021/acschembio.8b00877

Antagonists for Constitutively Active Mutant Estrogen Receptors : Insights into the Roles of Antiestrogen-Core and Side-Chain. / Sharma, Abhishek; Toy, Weiyi; Guillen, Valeria Sanabria; Sharma, Naina; Min, Jian; Carlson, Kathryn E.; Mayne, Christopher G.; Lin, Shengjia; Sabio, Michael; Greene, Geoffrey; Katzenellenbogen, Benita S.; Chandarlapaty, Sarat; Katzenellenbogen, John A.

In: ACS chemical biology, Vol. 13, No. 12, 21.12.2018, p. 3374-3384.

Research output: Contribution to journalArticle

Sharma, A, Toy, W, Guillen, VS, Sharma, N, Min, J, Carlson, KE, Mayne, CG, Lin, S, Sabio, M, Greene, G, Katzenellenbogen, BS, Chandarlapaty, S & Katzenellenbogen, JA 2018, 'Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain', ACS chemical biology, vol. 13, no. 12, pp. 3374-3384. https://doi.org/10.1021/acschembio.8b00877
Sharma, Abhishek ; Toy, Weiyi ; Guillen, Valeria Sanabria ; Sharma, Naina ; Min, Jian ; Carlson, Kathryn E. ; Mayne, Christopher G. ; Lin, Shengjia ; Sabio, Michael ; Greene, Geoffrey ; Katzenellenbogen, Benita S. ; Chandarlapaty, Sarat ; Katzenellenbogen, John A. / Antagonists for Constitutively Active Mutant Estrogen Receptors : Insights into the Roles of Antiestrogen-Core and Side-Chain. In: ACS chemical biology. 2018 ; Vol. 13, No. 12. pp. 3374-3384.
@article{064ebb0e243c4dc9b8c712a1845090e6,
title = "Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain",
abstract = "A major risk for patients having estrogen receptor α (ERα)-positive breast cancer is the recurrence of drug-resistant metastases after initial successful treatment with endocrine therapies. Recent studies have implicated a number of activating mutations in the ligand-binding domain of ERα that stabilize the agonist conformation as a prominent mechanism for this acquired resistance. There are several critical gaps in our knowledge regarding the specific pharmacophore requirements of an antagonist that could effectively inhibit all or most of the different mutant ERs. To address this, we screened various chemotypes for blocking mutant ER-mediated transcriptional signaling and identified RU58668 as a model compound that contains structural elements that support potent ligand-induced inhibition of mutant ERs. We designed and synthesized a focused library of novel antagonists and probed how small and large perturbations in different ligand structural regions influenced inhibitory activity on individual mutant ERs in breast cancer cells. Effective inhibition derives from both nonpolar and moderately polar motifs in a multifunctional side chain of the antagonists, with the nature of the ligand core making important contributions by increasing the potency of ligands possessing similar types of side chains. Some of our new antagonists potently blocked the transcriptional activity of the three most common mutant ERs (L536R, Y537S, D538G) and inhibited mutant ER-mediated cell proliferation. Supported by our molecular modeling, these studies provide new insights into the role of specific components, involving both the ligand core and multifunctional side chain, in suppressing wild-type and mutant ER-mediated transcription and breast cancer cell proliferation.",
author = "Abhishek Sharma and Weiyi Toy and Guillen, {Valeria Sanabria} and Naina Sharma and Jian Min and Carlson, {Kathryn E.} and Mayne, {Christopher G.} and Shengjia Lin and Michael Sabio and Geoffrey Greene and Katzenellenbogen, {Benita S.} and Sarat Chandarlapaty and Katzenellenbogen, {John A.}",
year = "2018",
month = "12",
day = "21",
doi = "10.1021/acschembio.8b00877",
language = "English (US)",
volume = "13",
pages = "3374--3384",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Antagonists for Constitutively Active Mutant Estrogen Receptors

T2 - Insights into the Roles of Antiestrogen-Core and Side-Chain

AU - Sharma, Abhishek

AU - Toy, Weiyi

AU - Guillen, Valeria Sanabria

AU - Sharma, Naina

AU - Min, Jian

AU - Carlson, Kathryn E.

AU - Mayne, Christopher G.

AU - Lin, Shengjia

AU - Sabio, Michael

AU - Greene, Geoffrey

AU - Katzenellenbogen, Benita S.

AU - Chandarlapaty, Sarat

AU - Katzenellenbogen, John A.

PY - 2018/12/21

Y1 - 2018/12/21

N2 - A major risk for patients having estrogen receptor α (ERα)-positive breast cancer is the recurrence of drug-resistant metastases after initial successful treatment with endocrine therapies. Recent studies have implicated a number of activating mutations in the ligand-binding domain of ERα that stabilize the agonist conformation as a prominent mechanism for this acquired resistance. There are several critical gaps in our knowledge regarding the specific pharmacophore requirements of an antagonist that could effectively inhibit all or most of the different mutant ERs. To address this, we screened various chemotypes for blocking mutant ER-mediated transcriptional signaling and identified RU58668 as a model compound that contains structural elements that support potent ligand-induced inhibition of mutant ERs. We designed and synthesized a focused library of novel antagonists and probed how small and large perturbations in different ligand structural regions influenced inhibitory activity on individual mutant ERs in breast cancer cells. Effective inhibition derives from both nonpolar and moderately polar motifs in a multifunctional side chain of the antagonists, with the nature of the ligand core making important contributions by increasing the potency of ligands possessing similar types of side chains. Some of our new antagonists potently blocked the transcriptional activity of the three most common mutant ERs (L536R, Y537S, D538G) and inhibited mutant ER-mediated cell proliferation. Supported by our molecular modeling, these studies provide new insights into the role of specific components, involving both the ligand core and multifunctional side chain, in suppressing wild-type and mutant ER-mediated transcription and breast cancer cell proliferation.

AB - A major risk for patients having estrogen receptor α (ERα)-positive breast cancer is the recurrence of drug-resistant metastases after initial successful treatment with endocrine therapies. Recent studies have implicated a number of activating mutations in the ligand-binding domain of ERα that stabilize the agonist conformation as a prominent mechanism for this acquired resistance. There are several critical gaps in our knowledge regarding the specific pharmacophore requirements of an antagonist that could effectively inhibit all or most of the different mutant ERs. To address this, we screened various chemotypes for blocking mutant ER-mediated transcriptional signaling and identified RU58668 as a model compound that contains structural elements that support potent ligand-induced inhibition of mutant ERs. We designed and synthesized a focused library of novel antagonists and probed how small and large perturbations in different ligand structural regions influenced inhibitory activity on individual mutant ERs in breast cancer cells. Effective inhibition derives from both nonpolar and moderately polar motifs in a multifunctional side chain of the antagonists, with the nature of the ligand core making important contributions by increasing the potency of ligands possessing similar types of side chains. Some of our new antagonists potently blocked the transcriptional activity of the three most common mutant ERs (L536R, Y537S, D538G) and inhibited mutant ER-mediated cell proliferation. Supported by our molecular modeling, these studies provide new insights into the role of specific components, involving both the ligand core and multifunctional side chain, in suppressing wild-type and mutant ER-mediated transcription and breast cancer cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=85057833273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057833273&partnerID=8YFLogxK

U2 - 10.1021/acschembio.8b00877

DO - 10.1021/acschembio.8b00877

M3 - Article

C2 - 30404440

AN - SCOPUS:85057833273

VL - 13

SP - 3374

EP - 3384

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 12

ER -